ArticleBMC endocrine disorders2025
Nomogram for predicting the risk of cervical lymph node metastases and recurrence in papillary thyroid carcinoma based on the thyroid differentiation score system and clinical characteristics.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual nomograms to predict central and lateral cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: a two-cohort study.Frontiers in endocrinology · 2026Article
- Identification of risk factors for high-risk dedifferentiation in papillary thyroid carcinoma and construction of discriminative model.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to identify independent predictors of cervical central lymph node metastasis (CLNM), cervical lateral lymph node metastasis (LLNM), and recurrence in patients with PTC, which could help guide the surgical management of these patients.
methodsThis retrospective study analyzed data from 542 patients with PTC, who underwent thyroid surgery and were enrolled in The Cancer Genome Atlas and Gene Expression Omnibus databases. Patients were categorized into two groups based on the presence or absence of cervical LNM, classified as CLNM or LLNM. Data were randomly partitioned into training and validation sets in a ratio of 7:3. Age, sex, thyroid differentiation score (TDS), and other relevant attributes, were compared between the two groups using univariate and multivariate analyses and reported as odds ratios (OR) or hazard ratios (HR) with 95% confidence intervals (CI). Independent predictors were identified and used to develop nomograms. To assess the accuracy, discrimination, and clinical utility of the prediction model, calibration, receiver operating characteristic (ROC), and decision curve analysis (DCA) were performed for both the training and validation sets.
resultsOf the 542 patients, 261 (48.15%) and 130 (23.99%) presented with CLNM and LLNM, respectively. The analyses identified several independent predictors for CLNM, including the presence of extrathyroidal invasion (OR 2.53, 95% CI 1.60-4.00), larger tumor dimension (OR 1.17, 95% CI 1.02-1.34), age over 55 years (OR 0.52, 95% CI 0.33-0.82), non-classic papillary subtype (OR 0.38, 95% CI 0.23-0.61), and lower TDS (OR 0.50, 95% CI 0.33-0.76). A greater number of excised cervical LNs (OR 12.30, 95% CI 4.35-34.77), the presence of CLNM (OR 1.07, 95% CI 1.04-1.10), and lower TDS (OR 0.09, 95% CI 0.04-0.21) were independent predictors for LLNM. Additionally, the independent predictors for relapse included age greater than 55 years (HR 1.87, 95% CI 1.00-3.49) and lower TDS (HR 0.35, 95% CI 0.20-0.62). These predictors were used to develop nomograms for CLNM, LLNM, and recurrence. ROC and DCA confirmed the discrimination and clinical utility of the models.
conclusionsThis study identified independent predictors of cervical CLNM, LLNM, and recurrence. Clinically relevant nomograms were developed that can assist in guiding cervical lymph node dissection and prediction of recurrence in patients with PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.